Filing Flows › Crispr Therapeutics AG (CRSP) › Q3 2026
Crispr Therapeutics AG (CRSP) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 2, 2026
Crispr Therapeutics AG (CRSP) reported revenue of $12.7M for the third quarter 2026 (Q3 2026), up 14-fold from a year earlier and +24% from the quarter before.
Crispr Therapeutics AG, Q3 2026: revenue $12.7M (14× year over year), net loss $111M, operating cash flow −$89.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $12.7M | +24% | 14× |
| Operating profit | −$130M | — | — |
| Net earnings | −$111M | — | — |
| Operating cash flow | −$89.7M | — | — |
What changed
Revenue was $12.7M in Q3 2026, up 1325% year over year and up 24% from the previous quarter. Collaboration Revenue was the largest line at 97% of revenue. Grant declined 61%.
Operating costs exceeded revenue by $130.0M, an operating margin of -1026.5%. Total costs grew 7% against revenue growth of 1325%. The fastest-growing cost line was Research & development (+22%). The quarter ended with a net loss of $111.4M, wider than the previous quarter's $91.2M loss.
Operating cash flow was −$89.7M. Non-cash charges added back $4.2M of depreciation and amortization and $18.0M of share-based compensation. Capital expenditures of $414K exceeded it, leaving free cash flow of −$90.1M.
Questions
What was Crispr Therapeutics AG's revenue in the third quarter 2026?
Crispr Therapeutics AG (CRSP) reported revenue of $12.7M for the third quarter 2026 (Q3 2026), up 14-fold from a year earlier and +24% from the quarter before.